{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"BTC-BGB","nct_id":"NCT04727996","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=btc-bgb-nct04727996. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BTC-BGB","arms":[{"description":"All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.","label":"Sitravatinib/Tislelizumab","type":"EXPERIMENTAL"}],"collaborators":["BeiGene"],"completion_date":{"date":"2024-12-31","type":"ESTIMATED"},"conditions":["Advanced Biliary Tract Cancer"],"enrollment":{"count":43,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sitravatinib","otherNames":["MGCD516"],"type":"DRUG"},{"name":"Tislelizumab","otherNames":["BGB-A317"],"type":"DRUG"}],"last_update":"2024-04-19","lead_sponsor":"Seoul National University Hospital","official_title":"Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Who Have Failed to At Least 1 Prior Systemic Treatment","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2023-07-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease control rate","timeFrame":"every 6weeks"}],"references":[{"citation":"Yoon J, Lee CK, Kim JW, Kang B, Park SJ, Kim JW, Chon HJ, Choi HJ, Lee MA, Kim TY, Oh DY. Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. J Hepatol. 2026 Apr;84(4):766-775. doi: 10.1016/j.jhep.2025.10.032. Epub 2025 Nov 24.","pmid":"41297674","type":"DERIVED"}],"start_date":{"date":"2020-11-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer","url":"https://clinicaltrials.gov/study/NCT04727996"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/btc-bgb-nct04727996"}